Key result
TM6SF2 E167K impairs hepatic triglyceride secretion by reducing cholesterol binding and ApoB interaction.
Why the study?
TM6SF2 is a key ER membrane protein involved in hepatic lipoprotein lipidation, but its structural basis and the impact of the E167K variant on lipidation were unclear.
Elucidates the structural mechanism by which the TM6SF2 E167K variant impairs hepatic VLDL lipidation, explaining its role in reducing coronary artery disease risk while increasing risk for steatotic liver disease.
TM6SF2 structures extend mechanistic insight into lipidation; leaves open targeted therapies for steatotic liver disease or CAD.
A missense variant in TM6SF2 (transmembrane 6 superfamily member 2, TM6SF2 E167K ) is a major risk factor for steatotic liver disease 1 , while protecting against coronary artery disease 2 . TM6SF2 is a polytopic resident protein of the smooth endoplasmic reticulum (ER) and ER-Golgi intermediate compartment that promotes lipidation of hepatic ApoB-containing lipoproteins before secretion into the circulation. Here, we used cryo-electron microscopy (cryo-EM) to determine the structures of TM6SF2 and TM6SF2 E167K . TM6SF2 comprises 10 transmembrane helices that bind a single cholesterol molecule within a transmembrane cavity. The protein assembles into homodimers and homotetramers that interact with ApoB. Structural and biochemical analyses show that the E167K substitution reduces cholesterol binding and ApoB interaction without disrupting overall protein structure. Expression of wild-type, but not mutant, TM6SF2 restores hepatic triglyceride secretion in TM6SF2-deficient hepatocytes. Together, these findings establish the structural framework for the bulk lipidation step in hepatic lipoprotein biogenesis, the principal pathway for hepatic triglyceride and cholesterol export into the circulation.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied Steatotic liver disease / Coronary artery disease. TM6SF2 E167K substitution vs. Wild-type TM6SF2 was evaluated on Protein structure, cholesterol binding, ApoB interaction, and hepatic triglyceride secretion. The TM6SF2 E167K variant reduces cholesterol binding and ApoB interaction without disrupting overall protein structure, impairing hepatic triglyceride secretion compared to wild-type.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: